Full access
New Research
Published Online: 1 January 2012

Combined Prolonged Exposure Therapy and Paroxetine for PTSD Related to the World Trade Center Attack: A Randomized Controlled Trial

Franklin R. Schneier, M.D., Yuval Neria, Ph.D., Martina Pavlicova, Ph.D., Elizabeth Hembree, Ph.D., Eun Jung Suh, Ph.D., Lawrence Amsel, M.D., M.P.H., and Randall D. Marshall, M.D.Authors Info & Affiliations
Publication: American Journal of Psychiatry
Volume 169, Number 1
https://doi.org/10.1176/appi.ajp.2011.11020321
PDF/EPUBformats

Abstract

Patients with PTSD from experiences during the World Trade Center attack responded better to paroxetine, up to 50 mg/day, than placebo over 10 weeks of exposure therapy that included weekly 90-minute guided imagery sessions and cognitive-behavioral exercises. By week 10, 42% of patients in the paroxetine group remitted, compared with 17% in the placebo group. The differences did not persist for patients who continued therapies beyond 10 weeks; by week 22, the remission rate was 45% for both treatments among those remaining in the study.

Abstract

Objective:

Selective serotonin reuptake inhibitors (SSRIs) are often recommended in combination with established cognitive-behavioral therapies (CBTs) for posttraumatic stress disorder (PTSD), but combined initial treatment of PTSD has not been studied under controlled conditions. There are also few studies of either SSRIs or CBT in treating PTSD related to terrorism. The authors compared prolonged exposure therapy (a CBT) plus paroxetine (an SSRI) with prolonged exposure plus placebo in the treatment of terrorism-related PTSD.

Method:

Adult survivors of the World Trade Center attack of September 11, 2001, with PTSD were randomly assigned to 10 weeks of treatment with prolonged exposure (10 sessions) plus paroxetine (N=19) or prolonged exposure plus placebo (N=18). After week 10, patients discontinued prolonged exposure and were offered 12 additional weeks of continued randomized treatment.

Results:

Patients treated with prolonged exposure plus paroxetine experienced significantly greater improvement in PTSD symptoms (incidence rate ratio=0.50, 95% CI=0.30–0.85) and remission status (odds ratio=12.6, 95% CI=1.23–129) during 10 weeks of combined treatment than patients treated with prolonged exposure plus placebo. Response rate and quality of life were also significantly more improved with combined treatment. The subset of patients who continued randomized treatment for 12 additional weeks showed no group differences.

Conclusions:

Initial treatment with paroxetine plus prolonged exposure was more efficacious than prolonged exposure plus placebo for PTSD related to the World Trade Center attack. Combined treatment medication and prolonged exposure therapy deserves further study in larger samples with diverse forms of PTSD and over longer follow-up periods.

Formats available

You can view the full content in the following formats:

View PDF/ePubView Full Text

Supplementary Material

File (appi.ajp.2011.11020321_ds001.pdf)

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Volume 169 • Number 1 • January 2012
Pages: 80 - 88
PubMed: 21908494

History

Received: 25 February 2011
Revision received: 20 May 2011
Revision received: 17 June 2011
Accepted: 24 June 2011
Published online: 1 January 2012
Published in print: January 2012

Authors

Affiliations

Franklin R. Schneier, M.D.
From the Trauma and Post Traumatic Stress Disorder Program, Anxiety Disorders Clinic, New York State Psychiatric Institute, New York; the Departments of Psychiatry and Biostatistics, Columbia University, New York; and the Department of Psychiatry, University of Pennsylvania, Philadelphia.
View all articles by this author
Yuval Neria, Ph.D.
From the Trauma and Post Traumatic Stress Disorder Program, Anxiety Disorders Clinic, New York State Psychiatric Institute, New York; the Departments of Psychiatry and Biostatistics, Columbia University, New York; and the Department of Psychiatry, University of Pennsylvania, Philadelphia.
View all articles by this author
Martina Pavlicova, Ph.D.
From the Trauma and Post Traumatic Stress Disorder Program, Anxiety Disorders Clinic, New York State Psychiatric Institute, New York; the Departments of Psychiatry and Biostatistics, Columbia University, New York; and the Department of Psychiatry, University of Pennsylvania, Philadelphia.
View all articles by this author
Elizabeth Hembree, Ph.D.
From the Trauma and Post Traumatic Stress Disorder Program, Anxiety Disorders Clinic, New York State Psychiatric Institute, New York; the Departments of Psychiatry and Biostatistics, Columbia University, New York; and the Department of Psychiatry, University of Pennsylvania, Philadelphia.
View all articles by this author
Eun Jung Suh, Ph.D.
From the Trauma and Post Traumatic Stress Disorder Program, Anxiety Disorders Clinic, New York State Psychiatric Institute, New York; the Departments of Psychiatry and Biostatistics, Columbia University, New York; and the Department of Psychiatry, University of Pennsylvania, Philadelphia.
View all articles by this author
Lawrence Amsel, M.D., M.P.H.
From the Trauma and Post Traumatic Stress Disorder Program, Anxiety Disorders Clinic, New York State Psychiatric Institute, New York; the Departments of Psychiatry and Biostatistics, Columbia University, New York; and the Department of Psychiatry, University of Pennsylvania, Philadelphia.
View all articles by this author
Randall D. Marshall, M.D.
From the Trauma and Post Traumatic Stress Disorder Program, Anxiety Disorders Clinic, New York State Psychiatric Institute, New York; the Departments of Psychiatry and Biostatistics, Columbia University, New York; and the Department of Psychiatry, University of Pennsylvania, Philadelphia.
View all articles by this author

Notes

Address correspondence to Dr. Schneier ([email protected]).

Funding Information

Dr. Schneier has received research funding from Forest Laboratories. Dr. Marshall is currently employed by Sunovion Pharmaceuticals. All other authors report no financial relationships with commercial interests.Supported by NIMH grant MH-068173 to Drs. Marshall and Schneier.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Item saved, go to cart
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share